Literature DB >> 8581515

Molecular evidence for the existence of disseminated zoster as a distinct entity in an immunosuppressed renal transplant patient.

E M Schlüpen1, H C Korting, F Nachbar, M Volkenandt.   

Abstract

Immunosuppressed renal transplant recipient are at substantially increased risk for the development of varicella zoster virus infections. They are also more prone than immunocompetent patients to develop atypical zoster and to experience a protracted course, and among them there is a higher frequency of generalized infections with possible fatal outcome. While establishing the diagnosis is essential to provide adequate therapy, conventional laboratory methods frequently fail to confirm the suspected infection. We report on a 47-year-old renal transplant recipient who developed multiple necrotic cutaneous ulcers under immunosuppressive treatment. While electron-microscopic analysis (negative staining) revealed no viral structures, varicella zoster virus specific DNA was detected by polymerase chain reaction in material obtained by a swab from these ulcers. Atypical herpetic infection should also be considered as a cause of disseminated ulcerative or necrotic skin lesions in immunosuppressed patients. Assays based on polymerase chain reaction are useful for the rapid confirmation or rejection of the suspected diagnosis of atypical herpetic infection.

Entities:  

Mesh:

Year:  1995        PMID: 8581515     DOI: 10.1007/bf00198905

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  22 in total

1.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

2.  [Disseminated herpes zoster in chronic lymphatic leukemia].

Authors:  W Grimm; H C Korting; W Stolz
Journal:  Hautarzt       Date:  1989-09       Impact factor: 0.751

3.  Skin complications in immunosuppressed patients: follow-up of kidney recipients.

Authors:  S Haim; R Friedman-Birnbaum; O S Better; S Tuma
Journal:  Br J Dermatol       Date:  1973-08       Impact factor: 9.302

4.  Varicella-Zoster infection in patients with cancer.

Authors:  S Schimpff; A Serpick; B Stoler; B Rumack; H Mellin; J M Joseph; J Block
Journal:  Ann Intern Med       Date:  1972-02       Impact factor: 25.391

5.  [Comparative evaluation of herpes virus detection using fluorescence-labeled monoclonal antibodies and electron microscopy negative contrast technic in dermatovenereologic diseases. Results of a pilot study of 30 patients].

Authors:  H C Korting; D Abeck; C Schmoeckel
Journal:  Hautarzt       Date:  1987-12       Impact factor: 0.751

6.  Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.

Authors:  C S Han; W Miller; R Haake; D Weisdorf
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

7.  A comparison of the Tzanck smear and viral isolation in varicella and herpes zoster.

Authors:  A R Solomon; J E Rasmussen; J S Weiss
Journal:  Arch Dermatol       Date:  1986-03

8.  Clinical manifestations of varicella-zoster virus infections in human immunodeficiency virus-infected children.

Authors:  I Srugo; V Israele; A E Wittek; T Courville; V M Vimal; P A Brunell
Journal:  Am J Dis Child       Date:  1993-07

9.  Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection.

Authors:  G T Nahass; B A Goldstein; W Y Zhu; U Serfling; N S Penneys; C L Leonardi
Journal:  JAMA       Date:  1992-11-11       Impact factor: 56.272

Review 10.  Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  J J O'Brien; D M Campoli-Richards
Journal:  Drugs       Date:  1989-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.